menu
    • menu
    [{"orgOrder":0,"company":"Remedy Plan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RPT1G","moa":"NAMPT","graph1":"Oncology","graph2":"Phase I","graph3":"Remedy Plan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Remedy Plan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Remedy Plan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Remedy Plan Therapeutics","sponsor":"Schooner Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Financing","leadProduct":"RPT1G","moa":"NAMPT","graph1":"Oncology","graph2":"Phase I","graph3":"Remedy Plan Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Oral Capsule","sponsorNew":"Remedy Plan Therapeutics \/ Schooner Capital","highestDevelopmentStatusID":"6","companyTruncated":"Remedy Plan Therapeutics \/ Schooner Capital"}]

    Find Clinical Drug Pipeline Developments & Deals by Remedy Plan Therapeutics

    Menu

    Remedy Plan Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Remedy Plan Therapeutics

                            U.S.A arrow
                            CRS
                            Not Confirmed

                            Remedy Plan Therapeutics

                            U.S.A arrow
                            CRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RPT1G

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Schooner Capital

                            Deal Size : $18.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Remedy Plan Raises $18M to Move RPT1G Into Phase 1/2 Trials

                            Details : The financing aims to advance the clinical development of RPT1G, a novel NAMPT inhibitor. It is being evaluated for the treatment ofacute myeloid leukemia.

                            Product Name : RPT1G

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            May 13, 2025

                            Lead Product(s) : RPT1G

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Schooner Capital

                            Deal Size : $18.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Remedy Plan Therapeutics

                            U.S.A arrow
                            CRS
                            Not Confirmed

                            Remedy Plan Therapeutics

                            U.S.A arrow
                            CRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RPT1G

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Remedy Plan Therapeutics Initiates Phase 1 Trial Of RPT1G, NAMPT Inhibitor

                            Details : RPT1G is a oral novel, small molecule NAMPT inhibitor, being investigated for acute myeloid leukemia and high-risk MDS.

                            Product Name : RPT1G

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 18, 2024

                            Lead Product(s) : RPT1G

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth